CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Open Calls for Patient Input

This page lists Common Drug Review (CDR) drug applications received by CADTH and the deadlines for filing patient group input for each drug. For more information about how to provide input, please visit the CDR Patient Input page

Ruzurgi (amifampridine)

Indications: Lambert-Eaton myasthenic syndrome

Call For Patient Input: September 8, 2020

Patient Input Closed: October 28, 2020

TBC (infliximab (subcutaneous))

Indications: Rheumatoid arthritis, Crohn’s disease, ulcerative colitis

Call For Patient Input: August 26, 2020

Patient Input Closed: October 16, 2020